What does anticholinergic property mean in medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What Anticholinergic Properties Mean in Medications

Anticholinergic properties refer to a medication's ability to block acetylcholine, a neurotransmitter in both the brain and peripheral tissues, by antagonizing muscarinic acetylcholine receptors. 1

Mechanism of Action

Medications with anticholinergic properties work by blocking muscarinic receptors, which are part of the parasympathetic nervous system. These drugs are more accurately described as "antimuscarinic" rather than broadly anticholinergic, as they primarily antagonize the parasympathetic system 2. The blockade occurs at various receptor sites throughout the body, leading to both therapeutic effects and adverse reactions 3.

Clinical Effects

Peripheral (Body) Effects:

  • Dry mouth (xerostomia)
  • Constipation
  • Blurred vision and visual impairments
  • Urinary retention
  • Dry eyes (xerophthalmia)

Central (Brain) Effects:

  • Cognitive impairment ranging from subtle deficits to severe decline
  • Confusion and delirium
  • Memory problems
  • Dementia-like symptoms 4

Common Medications with Anticholinergic Properties

High anticholinergic activity (>15 pmol/mL atropine equivalents): amitriptyline, atropine, clozapine, dicyclomine, doxepin, thioridazine, and tolterodine 5

Moderate anticholinergic activity (5-15 pmol/mL): chlorpromazine, diphenhydramine, nortriptyline, olanzapine, oxybutynin, and paroxetine 5

Psychotropic medications are particularly likely to possess anticholinergic properties, including certain antipsychotics (especially older phenothiazines) and tricyclic antidepressants 2. Examples from recent guidelines include olanzapine and quetiapine as drugs with anticholinergic properties, while aripiprazole and risperidone lack these properties 6.

The Anticholinergic Burden Concept

The cumulative effect of taking multiple medications with anticholinergic properties simultaneously creates an "anticholinergic burden." 1 This is critical because one-third to one-half of medications commonly prescribed to older adults have some degree of anticholinergic activity 1. The toxicity often results from the cumulative burden of multiple medications and their metabolites rather than a single drug 4.

Clinical Significance

The anticholinergic burden predicts adverse health outcomes including:

  • Cognitive and functional impairments in older adults 1
  • Increased risk of falls
  • Poorer clinical outcomes overall 7

Elderly patients and those with mental illness are particularly vulnerable to anticholinergic adverse effects, as they may already have baseline cognitive impairment 3.

Important Clinical Considerations

When Stopping Anticholinergic Medications:

Anticholinergic drugs must be tapered rather than abruptly discontinued to minimize cholinergic rebound, except in urgent situations like anticholinergic delirium or toxicity 6. When switching from a drug with anticholinergic properties (e.g., olanzapine, quetiapine) to one without (e.g., aripiprazole, risperidone), cross-tapering is advisable to avoid cholinergic rebound 6.

Common Pitfall:

Not all sedating medications are anticholinergic. Many sedating drugs like quetiapine and mirtazapine have potent antihistaminic but low anticholinergic properties—their sedation is not due to anticholinergic effects 7. This distinction matters when assessing anticholinergic burden.

Dose-Dependency:

Anticholinergic effects are often dose-dependent, meaning higher doses produce stronger anticholinergic effects 2. Some medications only demonstrate anticholinergic activity at higher concentrations or in patients with above-average drug levels 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.